Cannabis Science Appoints Three Distinguished Physicians as New Members to its Scientific Advisory Board

Cannabis Science Appoints Three Distinguished Physicians As New Members To Its Scientific Advisory Board: Dr. Ben Johnson, Dr. Alan Shackleford, and Dr. William Courtney
COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Cannabis Science Inc. (NASD OTCBB: CBIS) an emerging pharmaceutical cannabis company, is honored to announce that Dr. Ben Johnson, Dr. Allan Shackleford and Dr. William Courtney have accepted its request to become members of its recently formed Scientific Advisory Board. The formation of the Scientific Advisory Board was announced on August 6th with the appointment of Dr. Mitch Earlywine Ph. D. as its first member, and the appointment Dr. Ritchard L. Fishman M.D. was announced on August 18th. Given the addition of several prominent scientists and physicians with their knowledge base, the company's clinical trials focus, product development, and design procedures for submitting products to the FDA can be advanced much faster.

Dr. Ben Johnson is a complementary and alternative medicine physician. After earning a degree in Osteopathy from the University of Health Sciences in Kansas City, he has since earned an M.D. degree and an N.M.D as well. He resigned as a founder and director of the Immune Recovery Clinic in Atlanta, Georgia after working there for several years to devote full time to The Healing Codes (A stress healing program that he uses to cure himself of Lou Gehbrig's disease). In addition, Dr. Johnson served in the armed forces during Vietnam and was a flight surgeon in the army reserve for many years. He was a Senior Aviation Medical Examiner for the FAA for 12 years.

Currently, Dr. Johnson is owner of Dr. Ben Johnson Services, LLC, a business that promotes products for natural health care. He consults regularly with patients and health care professionals across the world, and his expertise is centered in the field of complimentary oncology.

Dr. Alan Shackleford, a Denver physician, is a graduate of University of Heidelburg School of Medicine. He has an extensive background in clinical medicine, nutrition support, metabolism analysis, micro vascular surgical techniques and stress management techniques in the treatment of obesity and performance anxiety. Aside from his clinical work, he was also an instructor in German and in genetics at the University of Maryland, and he was also a lecturer at Harvard medical school in clinical training for behavioral medicine.

Dr. William L. Courtney has an extensive medical education that began with a Bachelor of Science in Microbiology from the University of Michigan. He also received his Doctor of Medicine from Wayne State University, and Interned for Residency in Psychiatry at California Pacific Medical Center and went on to earned his Post Doctorate in Forensic Examination and Forensic Medicine. Dr. Courtney is currently a member of International Cannabinoid Research Society, the International Association of Cannabis as Medicine, and the Society of Clinical Cannabis. Dr. Courtney has also been teaching Continuing Medical Education (CME) courses in clinical cannabis. He also hosted the 2nd International CB2 Conference in Ft Bragg, California, and teaches a Survey Course on Endogenous Cannabinoid System for College of the Redwoods. He also works with dispensaries interested in providing medical marijuana to patients.

Dr. Robert Melamede, Ph. D., Cannabis Science Inc., President & CEO said, "We have been enormously gratified by the very positive reaction to the company's plans by those who are most familiar with the need for medical cannabis products. The fact that so many prominent experts understand the importance of what we are doing and support our efforts shows that we are on the right path. We are putting together a very powerful team and with their help we will successfully blend the revolutionary power of capitalism with activism moving the company forward."

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Contact:

Cannabis Science Inc.
Dr. Robert J. Melamede, 1-888-889-0888
President & CEO
[email protected] e-mail address is being protected from spambots. You need JavaScript enabled to view it
www.cannabisscience.com
or
Peter Glaser, 1-888-889-0888
Investor Relations
[email protected] e-mail address is being protected from spambots. You need JavaScript enabled to view it
www.cannabisscience.com

 

Suggested Articles

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.

Going from being the CSO of Bristol Myers Squibb to running one of the biggest cancer research organizations in the world is a major career shift.

Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development.